JP2025511819A - Ｎｌｒｐ３阻害剤としての縮合ピリダジン誘導体 - Google Patents

Ｎｌｒｐ３阻害剤としての縮合ピリダジン誘導体 Download PDF

Info

Publication number
JP2025511819A
JP2025511819A JP2024559337A JP2024559337A JP2025511819A JP 2025511819 A JP2025511819 A JP 2025511819A JP 2024559337 A JP2024559337 A JP 2024559337A JP 2024559337 A JP2024559337 A JP 2024559337A JP 2025511819 A JP2025511819 A JP 2025511819A
Authority
JP
Japan
Prior art keywords
substituted
independently selected
substituents independently
halo
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024559337A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511819A5 (https=
Inventor
イー． アダムス、マーク
ダブリュー． ブラウン、ジェイソン
チャン、エドコン
タン、ミンナム
モネンシャイン、ホルガー
シュライヒャー、クリスティン
スン、フイカイ
チョウ、フェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2025511819A publication Critical patent/JP2025511819A/ja
Publication of JP2025511819A5 publication Critical patent/JP2025511819A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2024559337A 2022-04-07 2023-04-07 Ｎｌｒｐ３阻害剤としての縮合ピリダジン誘導体 Pending JP2025511819A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263328709P 2022-04-07 2022-04-07
US63/328,709 2022-04-07
PCT/IB2023/053561 WO2023194964A1 (en) 2022-04-07 2023-04-07 Fused pyridazine derivatives as nlrp3 inhibitors

Publications (2)

Publication Number Publication Date
JP2025511819A true JP2025511819A (ja) 2025-04-16
JP2025511819A5 JP2025511819A5 (https=) 2026-04-13

Family

ID=86329425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024559337A Pending JP2025511819A (ja) 2022-04-07 2023-04-07 Ｎｌｒｐ３阻害剤としての縮合ピリダジン誘導体

Country Status (6)

Country Link
US (1) US20250340563A1 (https=)
EP (1) EP4504733A1 (https=)
JP (1) JP2025511819A (https=)
AR (1) AR129012A1 (https=)
TW (1) TW202345838A (https=)
WO (1) WO2023194964A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
TW202319055A (zh) * 2021-07-21 2023-05-16 日商安斯泰來製藥股份有限公司 縮環噠嗪（ｐｙｒｉｄａｚｉｎｅ）化合物
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AR119731A1 (es) * 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
WO2022135567A1 (zh) * 2020-12-25 2022-06-30 上海拓界生物医药科技有限公司 一类含哒嗪的化合物及其医药用途
TW202319055A (zh) * 2021-07-21 2023-05-16 日商安斯泰來製藥股份有限公司 縮環噠嗪（ｐｙｒｉｄａｚｉｎｅ）化合物

Also Published As

Publication number Publication date
WO2023194964A1 (en) 2023-10-12
TW202345838A (zh) 2023-12-01
AR129012A1 (es) 2024-07-03
US20250340563A1 (en) 2025-11-06
EP4504733A1 (en) 2025-02-12

Similar Documents

Publication Publication Date Title
JP7566888B2 (ja) アゾール縮合ピリダジン－３（２ｈ）－オン誘導体
US12005054B2 (en) Piperidinyl-3-(aryloxy)propanamides and propanoates
US9475816B2 (en) Substituted-1,4-dihydropyrazolo[4,3-b]indoles
JP2025511819A (ja) Ｎｌｒｐ３阻害剤としての縮合ピリダジン誘導体
JP2022535672A (ja) ＭＲＧＸ２の阻害薬である３－アミノ－４Ｈ－ベンゾ［ｅ］［１，２，４］チアジアジン１，１－ジオキシド誘導体
ES2976515T3 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad del receptor APJ
JP2026503702A (ja) 神経変性疾患の処置に有用な１－アミノ－４－フェニルフタラジン誘導体
WO2024033845A1 (en) Heterocyclic compound
EP4694980A1 (en) Pyrazolopyrimidine derivatives as inhibitors of nlrp3
JP2025179155A (ja) Ｓｓｔｒ４アゴニストとしてのｎ－ヘテロアリールアルキル－２－（ヘテロシクリル及びヘテロシクリルメチル）アセトアミド誘導体
JP2025511255A (ja) Ｎ－（ピロリジン－３－イルまたはピペリジン－４－イル）アセトアミド誘導体
JP7734147B2 (ja) Ｓｓｔｒ４アゴニストとしてのｎ－（ヘテロシクリル及びヘテロシクリルアルキル）－３－ベンジルピリジン－２－アミン誘導体
WO2025233837A1 (en) 4h-pyrimido[1,2-a]pyrimidin-4-one derivatives for use as nlrp3 inflammasome inhibitors for the treatment of neurodegenerative disorder
WO2025074305A1 (en) N-(1-(aminomethyl)cyclopropyl)(aryl or heteroaryl) carboxamide derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260403